
|Videos|October 9, 2021
Results from phase 3 YOSEMITE and RHINE trials on faricimab in DMO
Author(s)OTE Staff Reports
Dr Caroline Baumal provides an overview of the efficacy, safety and durability of faricimab in diabetic macular oedema (DMO) at ASRS 2021.
Advertisement
Dr Caroline Baumal provides an overview of the efficacy, safety and durability of faricimab in diabetic macular oedema (DMO) at ASRS 2021. In her presentation, Dr Baumal highlights results from the Phase 3 YOSEMITE and RHINE trials.
The American Society of Retina Specialists (ASRS) is hosting its 39th Annual Scientific Meeting from 8-12 October 2021, at the JW Marriott San Antonio Hill Country Resort and Spa in San Antonio, Texas.
Related Content:
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
AI-predicted retinal function shows promise in geographic atrophy
2
Mulling over options for mitigating severe vision loss from diabetes
3
Demodex blepharitis: Closing the diagnostic gap to improve ocular surface health
4
Trehalose-hyaluronate combination aids tear film after eyelid surgery
5






















